Allergan Recalls Lumigan Bimatoprost Ophthalmic Solution Due to Impurity Failures
Allergan is recalling 56,878 bottles of Lumigan (bimatoprost) 0.01% ophthalmic solution because the product failed impurities and degradation specifications.
The agency’s classification
FDA (Drugs): Class III
Class III is a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 1/5 (Low).
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The FDA classified this recall as Class III, which the rubric defines as typically resulting in a score of 1 or 2 because it is unlikely to cause adverse health consequences.
Plain-English summary
Allergan Sales, LLC is voluntarily recalling 56,878 bottles of Lumigan (bimatoprost ophthalmic solution) 0.01%, 7.5 mL, prescription only. The recall is limited to Lot #92577 with an expiration date of June 2018. The product was distributed nationwide in the United States.
The recall was initiated because the product failed impurities and degradation specifications. The U.S. Food and Drug Administration has classified this recall as Class III, which indicates that use of or exposure to the product is not likely to cause adverse health consequences.
Consumers and healthcare providers should stop using the affected product and contact their pharmacist or healthcare provider for guidance on replacement or disposal. The recall number is D-0667-2017.
The recalled product
- Product
- LUMIGAN (BIMATOPROST)
- Brand
- LUMIGAN
- Manufacturer
- Allergan Sales, LLC
- Category
- Drug — Ophthalmic
- Hazard
- Affected units
- 56,878
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 92577
- Exp. JUN 2018
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · LUMIGAN
- LowAllergan Recalls Lumigan Bimatoprost Ophthalmic Solution Due to Impurities
FDA (Drugs) · 2017-11-22
Same manufacturer · Allergan Sales, LLC
See all →- HighKeller Funnel 2 breast implant insertion devices recalled for potential coating defect
FDA (Devices) · 2024-05-08
- ModerateAllergan Recalls 72 Bottles of Combigan Eye Drops for cGMP Deviations
FDA (Drugs) · 2019-04-03
- LowAllergan Recalls Combigan Eye Drops Due to Failed Impurity Specifications
FDA (Drugs) · 2017-11-22
- SevereAllergan Recalls Blephamide Ophthalmic Ointment Due to Impurity Failures
FDA (Drugs) · 2017-07-05
- SevereAllergan Recalls Tazorac Gel 0.05% Due to Content Uniformity Failures
FDA (Drugs) · 2016-10-19
Same hazard · impurities
See all →- ModerateCipla Recalls Fosfomycin Tromethamine Due to Impurity Specification Failures
FDA (Drugs) · 2026-10-14
- LowSun Pharmaceutical Recalls Tretinoin Cream Due to Impurity Failures
FDA (Drugs) · 2026-10-14
- LowSun Pharmaceutical Recalls Tretinoin Cream Due to Impurity Failures
FDA (Drugs) · 2026-10-14
- LowSun Pharmaceutical Recalls Tretinoin Cream Due to Impurity Specifications
FDA (Drugs) · 2026-10-14
- LowMacleods Recalls Olanzapine Tablets Due to Impurity Levels
FDA (Drugs) · 2026-09-30
Similar recalls
- LowAllergan Recalls Lumigan Bimatoprost Ophthalmic Solution Due to Impurities
FDA (Drugs) · 2017-11-22
- LowAllergan Recalls Combigan Eye Drops Due to Failed Impurity Specifications
FDA (Drugs) · 2017-11-22
- LowLupin Recalls Bimatoprost Ophthalmic Solution Due to Impurity Failures
FDA (Drugs) · 2019-02-13
- LowLupin Recalls Bimatoprost Ophthalmic Solution Due to Impurity Specifications
FDA (Drugs) · 2020-01-08
- ModerateAllergan Recalls 72 Bottles of Combigan Eye Drops for cGMP Deviations
FDA (Drugs) · 2019-04-03
- SevereAllergan Recalls Blephamide Ophthalmic Ointment Due to Impurity Failures
FDA (Drugs) · 2017-07-05